Editas halts development of first clinical CRISPR program

Editas Medicine, one of a small handful of original CRISPR companies, announced Thursday that it was halting development of its first clinical program after data showed that only a small subset of patients responded.

Edit-101, an experimental CRISPR-based treatment for a rare eye disease called CEP290 mediated by LCA10, led to “clinically meaningful” vision improvements in just three of 14 patients treated in the company’s Phase I trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days for free!


Leave a Comment

Your email address will not be published. Required fields are marked *